$BIOCQ
Biocept Inc

2019 Q4 Form 10-K Financial Statement

#000156459020013670 Filed on March 27, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $1.784M $1.529M $1.191M
YoY Change 107.53% 100.8% 44.89%
Cost Of Revenue $2.870M $2.833M $2.673M
YoY Change 17.85% 14.14% -0.98%
Gross Profit -$1.090M -$1.303M -$1.482M
YoY Change -30.83% -24.23% -21.06%
Gross Profit Margin -61.11% -85.24% -124.4%
Selling, General & Admin $3.400M $3.163M $3.291M
YoY Change 10.62% -1.1% 4.74%
% of Gross Profit
Research & Development $1.160M $1.164M $1.148M
YoY Change -10.0% 6.77% 12.66%
% of Gross Profit
Depreciation & Amortization $240.0K $240.2K $228.9K
YoY Change 9.09% 7.62% 29.0%
% of Gross Profit
Operating Expenses $4.560M $4.326M $4.439M
YoY Change 4.53% 0.9% 6.68%
Operating Profit -$5.650M -$5.630M -$5.921M
YoY Change -4.85% -6.3% -1.95%
Interest Expense -$60.00K $62.03K $63.57K
YoY Change -25.0% -2.72% -24.53%
% of Operating Profit
Other Income/Expense, Net $0.00 -$62.03K -$1.895M
YoY Change -100.0% 55.85% 1558.53%
Pretax Income -$5.710M -$5.692M -$7.816M
YoY Change -4.99% -5.89% 27.03%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.710M -$5.692M -$7.816M
YoY Change -5.06% -5.89% 27.03%
Net Earnings / Revenue -320.11% -372.19% -656.08%
Basic Earnings Per Share -$0.20 -$2.47 -$0.38
Diluted Earnings Per Share -$0.20 -$2.47 -$0.38
COMMON SHARES
Basic Shares Outstanding 29.13M 2.302M 20.47M
Diluted Shares Outstanding 29.13M 2.302M 20.47M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.300M $6.540M $12.59M
YoY Change 171.93% -27.01% 389.88%
Cash & Equivalents $9.301M $6.539M $12.59M
Short-Term Investments
Other Short-Term Assets $300.0K $500.0K $590.0K
YoY Change -30.23% -21.88% -30.59%
Inventory $768.0K $687.2K $605.5K
Prepaid Expenses
Receivables $3.527M $2.862M $2.209M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.89M $10.59M $15.99M
YoY Change 131.12% -9.14% 196.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.504M $1.325M $1.219M
YoY Change -45.09% -54.3% -57.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.840M $3.936M $3.914M
YoY Change 40.18% 35.62% 35.36%
TOTAL ASSETS
Total Short-Term Assets $13.89M $10.59M $15.99M
Total Long-Term Assets $3.840M $3.936M $3.914M
Total Assets $17.73M $14.52M $19.90M
YoY Change 102.65% -0.21% 140.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.012M $1.834M $2.021M
YoY Change -1.37% 2.46% 21.72%
Accrued Expenses $1.980M $1.847M $1.491M
YoY Change 2.69% -5.28% -19.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $130.0K $260.0K
YoY Change 8.33% -21.21%
Long-Term Debt Due $720.0K $780.0K $640.0K
YoY Change 12.5% 36.84% -3.03%
Total Short-Term Liabilities $5.559M $5.783M $5.822M
YoY Change 20.59% 30.25% 29.09%
LONG-TERM LIABILITIES
Long-Term Debt $970.0K $1.030M $860.0K
YoY Change -2.02% 0.98% -18.87%
Other Long-Term Liabilities $0.00 $0.00 $120.0K
YoY Change -100.0% -100.0% -40.0%
Total Long-Term Liabilities $970.0K $1.032M $983.4K
YoY Change -11.67% -12.1% -21.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.559M $5.783M $5.822M
Total Long-Term Liabilities $970.0K $1.032M $983.4K
Total Liabilities $6.532M $6.815M $6.805M
YoY Change 14.44% 21.49% 18.15%
SHAREHOLDERS EQUITY
Retained Earnings -$245.7M -$240.0M -$234.3M
YoY Change 11.46%
Common Stock $256.9M $247.7M $247.4M
YoY Change 14.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.20M $7.705M $13.10M
YoY Change
Total Liabilities & Shareholders Equity $17.73M $14.52M $19.90M
YoY Change 102.65% -0.2% 140.11%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$5.710M -$5.692M -$7.816M
YoY Change -5.06% -5.89% 27.03%
Depreciation, Depletion And Amortization $240.0K $240.2K $228.9K
YoY Change 9.09% 7.62% 29.0%
Cash From Operating Activities -$5.470M -$5.610M -$6.720M
YoY Change 0.92% 2.75% 13.9%
INVESTING ACTIVITIES
Capital Expenditures -$440.0K -$210.0K -$60.00K
YoY Change 162.5% 200.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$440.0K -$210.0K -$60.00K
YoY Change 162.5% 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.670M -230.0K 4.600M
YoY Change -7981.82% -101.93% -689.74%
NET CHANGE
Cash From Operating Activities -5.470M -5.610M -6.720M
Cash From Investing Activities -440.0K -210.0K -60.00K
Cash From Financing Activities 8.670M -230.0K 4.600M
Net Change In Cash 2.760M -6.050M -2.180M
YoY Change -149.91% -194.98% -67.46%
FREE CASH FLOW
Cash From Operating Activities -$5.470M -$5.610M -$6.720M
Capital Expenditures -$440.0K -$210.0K -$60.00K
Free Cash Flow -$5.030M -$5.400M -$6.660M
YoY Change -7.2% 0.37% 13.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4609647
CY2018Q4 us-gaap Cash
Cash
3423373
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1574325
CY2018Q4 us-gaap Inventory Net
InventoryNet
587222
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
425961
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6010881
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2739422
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
729330
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1606387
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
641536
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5558812
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
985015
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
113122
CY2019 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
121572
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25259611
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2019 bioc Adjustment To Additional Paid In Capital Warrant Inducement Expense
AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense
1831116
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800905
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
931655
CY2019 bioc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
-158341
CY2018 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
38499
CY2019 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
-14167
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
623412
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
869579
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
29426
CY2019 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
1831116
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
380899
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1952753
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
50021
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
194928
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-488505
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-523293
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
601872
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14838
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
460972
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
210152
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-202609
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-116681
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22355218
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23049261
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145253
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
735300
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145253
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-735300
CY2018 bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
25693474
CY2019 bioc Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
25744997
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1200
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2513173
CY2019 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2337298
CY2018 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
160381
CY2019 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
539415
CY2018 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
559092
CY2019 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
393459
CY2018 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1197968
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23777233
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29662594
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1276762
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5878033
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2146611
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3423373
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9301406
CY2018 us-gaap Interest Paid Net
InterestPaidNet
605485
CY2019 us-gaap Interest Paid Net
InterestPaidNet
249984
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4517
CY2018 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
488000
CY2019 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
393000
CY2019 bioc Financial Guarantee Insurance Contracts Cancelled Premium Remaining Principal Outstanding
FinancialGuaranteeInsuranceContractsCancelledPremiumRemainingPrincipalOutstanding
0
CY2018 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
279000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
632000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
25000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
32000
CY2019 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y
CY2019 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
9700000
CY2019 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1400000
CY2018Q3 bioc Aggregate Number Of Units Sold Pursuant To Right Offering
AggregateNumberOfUnitsSoldPursuantToRightOffering
11587
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.53
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11600000
CY2018Q3 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y
CY2018Q3 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
8400000
CY2018Q3 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
1400000
CY2018Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1584571
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
504764
CY2018Q3 bioc Shares Available For Public Offering
SharesAvailableForPublicOffering
642438
CY2018Q3 us-gaap Share Price
SharePrice
3.285
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
CY2018Q3 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
2000000
CY2018Q3 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
300000
CY2018Q3 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
636000
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
990000
CY2019Q1 us-gaap Share Price
SharePrice
2.25
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
2000000
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6800000
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.405
CY2018Q1 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
122000
CY2019Q1 bioc Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
7600000
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5950000
CY2019Q1 us-gaap Share Price
SharePrice
1.37
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2019Q1 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y6M
CY2019Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6000000
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1925000
CY2019Q4 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
6400000
CY2019Q4 bioc Offering Fees And Costs Recorded Within Common Stock Issuance Costs As An Offset To Additional Paid In Capital
OfferingFeesAndCostsRecordedWithinCommonStockIssuanceCostsAsAnOffsetToAdditionalPaidInCapital
998000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was founded in California in May 1997 and <font style="color:#000000;">is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company&#8217;s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company&#8217;s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient&#8217;s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company&#8217;s pathology partnership program, branded as Empower TC</font><font style="color:#000000;font-size:7.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> TM</sup></font><font style="color:#000000;">, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company&#8217;s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.</font></p> <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company&#8217;s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July&#160;23, 2013.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company&#8217;s services such as Medicare, insurance companies, and other third-party payers. The Company&#8217;s client base consists of a large number of geographically dispersed clients diversified across various customer types.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the years ended December 31, 2018 and 2019 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and 2019 were as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.7%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived most revenues only from within the United States.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company&#8217;s current or planned products are currently sourced from one supplier, for which alternative suppliers exist but the Company has not validated the product(s) of such alternative supplier(s), and substitutes for these components may not be obtained easily or may require substantial design or manufacturing modifications. </p>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to accounts receivable, inventories, long-lived assets, income taxes, revenues, stock-based compensation, and the determination of the Company&#8217;s ability to continue as a going concern. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2019Q4 bioc Aggregate Net Interest Bearing Indebtedness
AggregateNetInterestBearingIndebtedness
1700000
CY2019Q4 bioc Other Non Interest Bearing Current Liabilities
OtherNonInterestBearingCurrentLiabilities
2800000
CY2019Q4 bioc Aggregate Net Interest Bearing Indebtedness Due Within One Year
AggregateNetInterestBearingIndebtednessDueWithinOneYear
724000
CY2018Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock.
CY2018 bioc Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
12703885
CY2019 bioc Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
19308013
CY2018 bioc Provisions For Contractual Discounts
ProvisionsForContractualDiscounts
3937993
CY2018 bioc Provisions For Aged Non Patient Receivables
ProvisionsForAgedNonPatientReceivables
326137
CY2018 bioc Provisions For Estimated Patient Receivables
ProvisionsForEstimatedPatientReceivables
66470
CY2018 bioc Provisions For Other Payer Specific Sales Allowances
ProvisionsForOtherPayerSpecificSalesAllowances
5122987
CY2017Q4 bioc Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
1193426
CY2018 bioc Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery
GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery
3250298
CY2018 bioc Gross And Net Accounts Receivable For Settlements Upon Adjudication
GrossAndNetAccountsReceivableForSettlementsUponAdjudication
-2869399
CY2018Q4 bioc Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
1574325
CY2019 bioc Gross And Net Accounts Receivable For Amounts Recognized Upon Delivery
GrossAndNetAccountsReceivableForAmountsRecognizedUponDelivery
5528566
CY2019 bioc Gross And Net Accounts Receivable For Settlements Upon Adjudication
GrossAndNetAccountsReceivableForSettlementsUponAdjudication
-3575813
CY2019Q4 bioc Gross And Net Accounts Receivable
GrossAndNetAccountsReceivable
3527078
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
one supplier
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018Q3 bioc Conversion Of Preferred Stock To Common Stock Conversion Price
ConversionOfPreferredStockToCommonStockConversionPrice
4.53
CY2018Q3 bioc Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering
ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering
10100000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 bioc Proceeds From Issuance Of Units Net Of Issuance Expenses Related To Rights Offering
ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering
2200000
CY2018Q3 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
3.30
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2018Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
535682
CY2019Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
622792
CY2018Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
712574
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
748742
CY2018Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
62767
CY2019Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
89562
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
158342
CY2018Q3 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
2.57
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
0.95
CY2019Q1 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
1.01
CY2019Q2 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
1.18
CY2019Q2 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
1800000
CY2019Q4 bioc Estimated Grant Date Fair Value Of Warrants
EstimatedGrantDateFairValueOfWarrants
0.24
CY2018Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2818583
CY2019Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2857538
CY2018Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
157391
CY2019Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
156987
CY2018Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1437408
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
203602
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
220253
CY2019Q1 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
149000
CY2019Q1 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q1 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2019Q1 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
5013
CY2019Q1 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
180000
CY2018Q1 bioc Unregistered Warrants Issued Grant Date Fair Value
UnregisteredWarrantsIssuedGrantDateFairValue
9700000
CY2019Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
1552891
CY2018Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2019Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
570173
CY2018Q4 bioc Finance Leased Assets Gross
FinanceLeasedAssetsGross
2573955
CY2018Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
116640
CY2019Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
625038
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7674150
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5762627
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4934728
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4258297
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
255426
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
298855
CY2019Q1 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-02
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
100000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
2706
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
130000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2023-05
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
245000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
36
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
8253
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
297000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2022-08
CY2019Q3 bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
89000
CY2019Q3 bioc Finance Lease Transaction Frequency Of Periodic Payment
FinanceLeaseTransactionFrequencyOfPeriodicPayment
monthly
CY2019Q3 bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
CY2019Q3 bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
1770
CY2019Q3 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
106000
CY2019Q3 bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2024-09
CY2019Q4 bioc Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
2335717
CY2019Q4 bioc Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1566781
CY2019Q4 bioc Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
973189
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
470486
CY2019 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
249984
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1272024
CY2019 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1992494
CY2019Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
779049
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
531846
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
408396
CY2019Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
284380
CY2019Q4 bioc Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
69674
CY2019Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2073345
CY2019Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
375827
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1697518
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Next Twelve Months
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueNextTwelveMonths
90260
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Two Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInTwoYears
69053
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Three Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInThreeYears
57499
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due In Four Years
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueInFourYears
58098
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due Thereafter
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueThereafter
9536
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Due
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue
284446
CY2019Q4 bioc Finance Leases Maintenance And Sales Tax Obligation Payments Net
FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsNet
284446
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
855136
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
855136
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12684
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
842452
CY2019 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
249984
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1430366
CY2019Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y7D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7M2D
CY2019Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.2193
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.045
CY2019 bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
142587
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28410
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
195820
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2676229
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
140026
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2732023
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2655129
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.20
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
57.96
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.41
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.91
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.70
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.66
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.74
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M9D
CY2019Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2018Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2019Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
91000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5867281
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30688025
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
228000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
215000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 bioc Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Decrease In Net Deferred Tax Assets
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDecreaseInNetDeferredTaxAssets
2600000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1886
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1886
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5159881
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5278232
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-670015
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-764997
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
118959
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
103617
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
11128
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
174128
CY2019 bioc Income Tax Reconciliation Warrant Inducement Expense
IncomeTaxReconciliationWarrantInducementExpense
384534
CY2019 bioc Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
35487
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
272314
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
359765
CY2018 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-132855
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
388
CY2019 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
325046
CY2018 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
8386
CY2019 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-4296
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19420
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-83353
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6079058
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5467443
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
13900000
CY2019 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
which will begin to expire in 2020
CY2018 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2019 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9229174
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13118923
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2958710
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3318475
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2864028
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4536147
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
64628
CY2019Q4 bioc Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
205542
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15116540
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21179087
CY2019Q4 bioc Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
569870
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
569870
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15116540
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20609217
CY2019Q4 bioc Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2019 bioc Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-31
CY2016Q1 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
1062500
CY2019 bioc Unconditional Purchase Commitment Frequency Of Periodic Payment
UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment
Quarterly
CY2019 us-gaap Unrecorded Unconditional Purchase Obligation Date
UnrecordedUnconditionalPurchaseObligationDate
2020-05-31
CY2018Q3 us-gaap Assets
Assets
14551892
CY2018Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1357193
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1258261
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1174397
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1098137
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6153101
CY2018 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
101000
CY2019 bioc Finance Leases Sales Tax And Maintenance Obligations Expense
FinanceLeasesSalesTaxAndMaintenanceObligationsExpense
122000
CY2018Q1 us-gaap Cash
Cash
9272420
CY2018Q2 us-gaap Cash
Cash
2569111
CY2018Q3 us-gaap Cash
Cash
8956200
CY2018Q1 us-gaap Assets
Assets
14747827
CY2018Q2 us-gaap Assets
Assets
8291310
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
8507714
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2527568
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
8938408
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
806943
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
822238
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
761591
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
859526
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
2434886
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
2699671
CY2018Q3 us-gaap Cost Of Revenue
CostOfRevenue
2481916
CY2018Q4 us-gaap Cost Of Revenue
CostOfRevenue
2435262
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1070584
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1019285
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1089746
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1288957
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1938664
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1708970
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1793720
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1632670
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1636542
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1433174
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1404192
CY2018Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1440798
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6273733
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6038862
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6007983
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5938161
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6356404
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-6047784
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-6014312
CY2018Q3 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
636370
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6356404
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6153101
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6684154
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6014312
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.70
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.70
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1911282
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2280115
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2767440
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4209221
CY2018Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1911282
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2280115
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2759614
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4209221
CY2019Q1 us-gaap Cash
Cash
14762198
CY2019Q2 us-gaap Cash
Cash
12590597
CY2019Q3 us-gaap Cash
Cash
6539444
CY2019Q1 us-gaap Assets
Assets
21891932
CY2019Q2 us-gaap Assets
Assets
19904840
CY2019Q3 us-gaap Assets
Assets
14520914
CY2019Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1452244
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
983419
CY2019Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1032243
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
14014084
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
13099551
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
7705458
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1024239
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1191323
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1529262
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1783742
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
2599364
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
2673323
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
2832735
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1223291
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1148280
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1163546
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1681837
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1676310
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1700380
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1374560
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1614732
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1462335
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5854813
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5921322
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5629734
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5916787
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7816012
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5691762
CY2019Q1 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
99743
CY2019Q4 bioc Deemed Dividend Related To Warrants Down Round Provision
DeemedDividendRelatedToWarrantsDownRoundProvision
21829
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6016530
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7816012
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5691762
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5735307
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20466224
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23018235
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29128632
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20466224
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23018235
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29128632

Files In Submission

Name View Source Status
0001564590-20-013670-index-headers.html Edgar Link pending
0001564590-20-013670-index.html Edgar Link pending
0001564590-20-013670.txt Edgar Link pending
0001564590-20-013670-xbrl.zip Edgar Link pending
bioc-10k_20191231.htm Edgar Link pending
bioc-20191231.xml Edgar Link completed
bioc-20191231.xsd Edgar Link pending
bioc-20191231_cal.xml Edgar Link unprocessable
bioc-20191231_def.xml Edgar Link unprocessable
bioc-20191231_lab.xml Edgar Link unprocessable
bioc-20191231_pre.xml Edgar Link unprocessable
bioc-ex231_8.htm Edgar Link pending
bioc-ex311_7.htm Edgar Link pending
bioc-ex312_9.htm Edgar Link pending
bioc-ex321_6.htm Edgar Link pending
bioc-ex322_10.htm Edgar Link pending
bioc-ex43_152.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending